CD4 and cancer: Naïve CD4+ T cells can differentiate into various effector cell lineages, such as Th1, Th2 and Th17 cells, which secrete different effector molecules and thereby characteristically shape the tumor microenvironment (TME) and the prognosis of cancer patients (34–36).